Key Drivers
- Cash Rich
- Strong Margins
- Tax Boost
AIAI Summary
AUPH has shifted from a speculative biotech into a cash-generating, self-funding commercial company with strong margins and a fortress balance sheet, so the key investment question is no longer survival but whether Lupkynis growth and any new strategic bets can sustain durable earnings power without execution slipping.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Rich
- •Strong Margins
- •Tax Boost
AUPH combines strong liquidity, low leverage, and healthy cash flow with high margins, but its earnings quality is distorted by a large tax benefit and the stock looks only fairly valued after normalization.
Price Behavior
Key Price Behavior Insights:
- •Lower-high pattern
- •Support holding
- •Weak close
AUPH has shifted into a short-term downtrend over the last month, with lower highs and lows and a close near support, so bulls need a reclaim of the $15.99–$16.25 resistance zone to improve the setup.
Rebounded from $15.14 to $16.25 on 2026-05-06, then faded back toward support
Sentiment & News
Key News Insights:
- •Earnings beat
- •Business update
- •Peer scrutiny
Aurinia Pharmaceuticals delivered a first-quarter earnings beat and broader business update, signaling improving near-term operating performance while remaining under peer comparison scrutiny.
The results are likely supportive for sentiment as they reinforce execution progress and may improve confidence in Aurinia's near-term financial trajectory
Similar Companies in Healthcare
Other companies in the same sector with AI ratings